Nifty
Sensex
:
:
11844.10
39434.72
187.05 (1.60%)
623.33 (1.61%)

Pharmaceuticals & Drugs

Rating :
76/99

BSE: 533573 | NSE: APLLTD

519.70
-8.95 (-1.69%)
24-May-2019 | 3:56PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  525.00
  •  529.95
  •  518.50
  •  528.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  15645
  •  81.31
  •  664.00
  •  414.40

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 9,901.80
  • 16.94
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 10,519.66
  • 0.76%
  • 3.64

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 72.97%
  • 0.99%
  • 9.88%
  • FII
  • DII
  • Others
  • 0.3%
  • 5.14%
  • 10.72%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 10.94
  • -0.37

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 11.50
  • -9.35

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 12.30
  • -16.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.23
  • 25.19
  • 23.69

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.03
  • 7.19
  • 5.30

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.08
  • 17.00
  • 14.81

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
926.95
853.31
8.63%
1,018.15
840.02
21.21%
1,127.06
789.29
42.79%
862.53
648.19
33.07%
Expenses
748.91
680.08
10.12%
775.92
652.49
18.92%
824.72
610.14
35.17%
711.54
546.77
30.14%
EBITDA
178.04
173.23
2.78%
242.23
187.53
29.17%
302.34
179.15
68.76%
150.99
101.42
48.88%
EBIDTM
19.21%
20.30%
23.79%
22.32%
26.83%
22.70%
17.51%
15.65%
Other Income
3.37
0.64
426.56%
3.52
0.33
966.67%
2.37
7.67
-69.10%
0.10
0.17
-41.18%
Interest
5.08
1.34
279.10%
5.95
0.82
625.61%
5.81
0.35
1,560.00%
1.57
0.89
76.40%
Depreciation
29.95
31.57
-5.13%
29.05
26.40
10.04%
28.63
25.65
11.62%
27.60
21.84
26.37%
PBT
146.38
140.96
3.85%
210.75
160.63
31.20%
270.27
160.82
68.06%
121.92
78.86
54.60%
Tax
14.90
38.52
-61.32%
40.00
29.78
34.32%
70.30
36.57
92.23%
31.54
15.48
103.75%
PAT
131.48
102.44
28.35%
170.75
130.85
30.49%
199.97
124.24
60.95%
90.38
63.38
42.60%
PATM
14.18%
12.01%
16.77%
15.58%
17.74%
15.74%
10.48%
9.78%
EPS
6.58
4.98
32.13%
9.01
6.93
30.01%
10.61
6.45
64.50%
4.80
3.54
35.59%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
3,934.69
3,130.81
3,134.61
3,165.99
2,056.13
1,863.22
1,520.35
1,465.41
1,202.05
Net Sales Growth
25.68%
-0.12%
-0.99%
53.98%
10.35%
22.55%
3.75%
21.91%
 
Cost Of Goods Sold
992.69
886.19
887.57
823.95
639.85
627.02
609.56
637.39
534.07
Gross Profit
2,942.00
2,244.62
2,247.04
2,342.04
1,416.28
1,236.20
910.78
828.02
667.97
GP Margin
74.77%
71.69%
71.68%
73.97%
68.88%
66.35%
59.91%
56.50%
55.57%
Total Expenditure
3,061.09
2,515.55
2,519.90
2,160.88
1,660.92
1,506.16
1,271.75
1,249.54
1,059.04
Power & Fuel Cost
-
70.35
64.20
58.89
43.31
32.07
26.66
29.57
24.58
% Of Sales
-
2.25%
2.05%
1.86%
2.11%
1.72%
1.75%
2.02%
2.04%
Employee Cost
-
622.81
558.83
472.85
306.76
247.00
193.79
168.46
149.21
% Of Sales
-
19.89%
17.83%
14.94%
14.92%
13.26%
12.75%
11.50%
12.41%
Manufacturing Exp.
-
244.53
289.79
209.91
263.38
272.44
191.95
183.83
145.34
% Of Sales
-
7.81%
9.24%
6.63%
12.81%
14.62%
12.63%
12.54%
12.09%
General & Admin Exp.
-
283.43
299.79
233.28
145.68
117.73
87.73
80.25
63.01
% Of Sales
-
9.05%
9.56%
7.37%
7.09%
6.32%
5.77%
5.48%
5.24%
Selling & Distn. Exp.
-
380.23
393.14
244.62
244.69
194.03
154.78
129.93
113.65
% Of Sales
-
12.14%
12.54%
7.73%
11.90%
10.41%
10.18%
8.87%
9.45%
Miscellaneous Exp.
-
28.01
26.58
117.38
17.26
15.86
7.27
20.11
29.17
% Of Sales
-
0.89%
0.85%
3.71%
0.84%
0.85%
0.48%
1.37%
2.43%
EBITDA
873.60
615.26
614.71
1,005.11
395.21
357.06
248.60
215.87
143.01
EBITDA Margin
22.20%
19.65%
19.61%
31.75%
19.22%
19.16%
16.35%
14.73%
11.90%
Other Income
9.36
34.87
2.58
8.83
12.09
4.44
16.71
16.31
21.01
Interest
18.41
3.40
5.23
5.43
3.81
10.40
23.98
37.55
27.59
Depreciation
115.23
105.46
82.97
72.21
44.41
40.49
34.97
33.65
29.59
PBT
749.32
541.27
529.09
936.30
359.07
310.61
206.35
160.98
106.84
Tax
156.74
120.36
122.19
216.12
76.35
75.10
41.10
30.85
21.46
Tax Rate
20.92%
22.24%
23.09%
23.08%
21.26%
24.18%
19.92%
19.16%
20.09%
PAT
592.58
420.72
406.99
720.18
282.72
235.51
165.25
130.13
85.39
PAT before Minority Interest
593.66
420.91
406.90
720.18
282.72
235.51
165.25
130.13
85.39
Minority Interest
1.08
-0.19
0.09
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
15.06%
13.44%
12.98%
22.75%
13.75%
12.64%
10.87%
8.88%
7.10%
PAT Growth
40.79%
3.37%
-43.49%
154.73%
20.05%
42.52%
26.99%
52.39%
 
Unadjusted EPS
31.00
21.89
21.39
38.19
15.01
12.49
8.77
6.90
4.53

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
2,220.14
1,902.33
1,597.36
884.64
675.57
502.94
395.00
296.73
Share Capital
37.70
37.70
37.70
37.70
37.70
37.70
37.70
11.00
Total Reserves
2,182.44
1,864.63
1,559.66
846.94
637.87
465.24
357.30
259.03
Non-Current Liabilities
597.10
94.15
84.02
72.44
94.32
103.25
122.07
150.80
Secured Loans
0.00
0.00
0.00
18.80
41.95
59.71
76.32
89.67
Unsecured Loans
500.00
0.00
0.00
0.00
10.27
10.83
18.54
38.81
Long Term Provisions
61.66
57.22
28.23
9.36
6.68
6.06
5.39
5.10
Current Liabilities
1,123.50
692.67
747.19
684.09
602.51
528.57
583.13
413.28
Trade Payables
759.32
500.73
565.65
324.94
288.44
239.96
209.15
138.57
Other Current Liabilities
142.89
81.28
51.80
44.56
60.62
69.25
151.60
84.90
Short Term Borrowings
207.78
88.51
113.71
219.70
25.42
70.11
138.43
146.28
Short Term Provisions
13.51
22.15
16.03
94.88
228.02
149.24
83.95
43.53
Total Liabilities
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81
Net Block
993.38
799.40
708.09
546.87
396.96
344.22
267.82
271.99
Gross Block
1,242.46
950.09
1,093.63
861.06
665.08
572.48
462.91
433.54
Accumulated Depreciation
249.08
150.69
385.54
314.19
268.12
228.26
195.09
161.55
Non Current Assets
2,116.31
1,316.80
917.30
750.43
515.81
415.66
364.35
308.30
Capital Work in Progress
1,010.15
396.28
92.52
83.14
20.67
32.26
58.24
26.50
Non Current Investment
41.64
49.88
53.43
2.26
3.36
3.30
3.30
3.26
Long Term Loans & Adv.
71.14
71.24
29.96
118.15
94.82
35.88
34.99
6.54
Other Non Current Assets
0.00
0.00
33.30
0.00
0.00
0.00
0.00
0.00
Current Assets
1,824.74
1,372.46
1,511.27
890.74
856.59
719.10
735.85
552.51
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
733.93
632.75
569.79
382.77
310.78
266.83
258.74
219.23
Sundry Debtors
526.34
338.82
350.48
361.17
273.37
232.87
199.33
201.97
Cash & Bank
89.92
159.60
450.83
26.83
23.96
16.11
47.09
6.29
Other Current Assets
474.55
7.56
7.09
0.00
248.48
203.29
230.68
125.02
Short Term Loans & Adv.
447.06
233.73
133.08
119.98
248.48
203.29
230.68
125.02
Net Current Assets
701.24
679.79
764.08
206.65
254.08
190.53
152.71
139.23
Total Assets
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
312.42
328.55
947.65
171.76
239.97
264.82
141.77
95.00
PBT
541.27
529.09
936.16
359.07
310.61
206.35
160.98
106.84
Adjustment
87.12
83.06
69.60
44.61
69.76
53.30
75.09
54.71
Changes in Working Capital
-180.85
-165.64
138.90
-162.50
-71.53
43.86
-61.59
-48.76
Cash after chg. in Working capital
447.54
446.51
1,144.66
241.18
308.84
303.51
174.48
112.79
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-135.12
-117.96
-197.01
-69.42
-68.87
-38.70
-32.71
-17.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-884.38
-485.91
-306.80
-255.61
-81.06
-67.02
-56.39
-56.82
Net Fixed Assets
-606.86
-121.60
-288.80
-200.26
-81.01
-83.59
-61.11
Net Investments
-195.85
-65.58
-4.13
0.00
-29.98
0.00
0.00
Others
-81.67
-298.73
-13.87
-55.35
29.93
16.57
4.72
Cash from Financing Activity
502.62
-128.88
-224.30
86.72
-151.06
-228.78
-44.58
-46.95
Net Cash Inflow / Outflow
-69.34
-286.24
416.55
2.86
7.86
-30.98
40.80
-8.77
Opening Cash & Equivalents
153.08
439.32
22.77
23.96
16.11
47.09
6.29
15.06
Closing Cash & Equivalent
83.74
153.08
439.32
26.83
23.96
16.11
47.09
6.29

Financial Ratios

Standalone /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
117.78
100.92
84.74
46.93
35.84
26.68
20.95
49.10
ROA
12.70%
15.90%
35.39%
18.76%
18.79%
14.79%
13.27%
9.92%
ROE
20.42%
23.25%
58.03%
36.24%
39.97%
36.81%
39.14%
31.62%
ROCE
22.15%
28.87%
65.87%
37.54%
43.54%
32.05%
28.93%
21.52%
Fixed Asset Turnover
2.86
3.07
3.24
2.71
3.02
2.95
3.28
2.79
Receivable days
50.43
40.13
41.02
55.91
49.38
51.58
49.79
60.94
Inventory Days
79.67
70.01
54.91
61.11
56.34
62.73
59.30
66.15
Payable days
98.47
84.03
83.80
69.83
66.49
69.05
51.02
50.77
Cash Conversion Cycle
31.63
26.12
12.13
47.19
39.23
45.26
58.07
76.32
Total Debt/Equity
0.32
0.05
0.07
0.30
0.16
0.37
0.89
1.21
Interest Cover
160.20
102.16
173.43
95.30
30.87
9.60
5.29
4.87

News Update:


  • Alembic Pharmaceuticals gets USFDA approval for Solifenacin Succinate Tablets
    21st May 2019, 10:27 AM

    Solifenacin Succinate Tablet is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

    Read More
  • Alembic Pharma - Quarterly Results
    8th May 2019, 16:05 PM

    Read More
  • Alembic Pharma partners with SPH Group & Adia for Chinese market
    7th May 2019, 16:03 PM

    SPH Sine, Alembic & Adia shall hold 51%, 44% & 5% equity in the JVA

    Read More
  • Alembic Pharmaceuticals’ JV gets EIR from USFDA for facility at Karkhadi
    6th May 2019, 11:10 AM

    USFDA has conducted inspection at Aleor's formulation facility at Karakhadi, Gujarat during the period from February 04, 2019 to February 08, 2019

    Read More
  • Alembic Pharma gets USFDA’s nod for Olopatadine Hydrochloride Ophthalmic Solution
    2nd May 2019, 11:18 AM

    Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is indicated for the treatment of ocular itching associated with allergic conjunctivitis

    Read More
  • Alembic Pharma gets USFDA’s nod for Tobramycin Ophthalmic Solution
    22nd Apr 2019, 11:08 AM

    Tobramycin Ophthalmic Solution is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria

    Read More
  • Alembic Pharma gets USFDA’s nod for Teriflunomide Tablets
    22nd Apr 2019, 10:58 AM

    Teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis

    Read More
  • Alembic Pharma gets USFDA’s nod for Bimatoprost Ophthalmic Solution
    15th Apr 2019, 10:37 AM

    Bimatoprost Ophthalmic Solution, 0.03% have an estimated market size of $76 million for twelve months ending December 2018 according to IQVIA

    Read More
  • Alembic Pharma gets EIR from USFDA for facility at Panelav
    5th Apr 2019, 08:57 AM

    USFDA has conducted inspection at the company’s formulation facility at Panelav during the period from October 22, 2018 to October 25, 2018

    Read More
  • Alembic Pharma gets USFDA’s nod for Tadalafil Tablets
    27th Mar 2019, 11:02 AM

    Alembic now has a total of 89 ANDA approvals from USFDA

    Read More
  • Alembic Pharma gets USFDA’s nod for Azelastine Hydrochloride Ophthalmic Solution
    22nd Mar 2019, 10:49 AM

    Azelastine Hydrochloride Ophthalmic Solution 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis

    Read More
  • Alembic Pharmaceuticals raises Rs 150 crore via NCDs
    19th Mar 2019, 11:15 AM

    The NCD Committee of the Company at its meeting held on March 19, 2019 has allotted the same

    Read More
  • Alembic Pharmaceuticals planning to raise Rs 150 crore via NCDs
    13th Mar 2019, 16:29 PM

    The company’s NCD committee will consider the same in the meeting to be held on March 19, 2019

    Read More
  • Alembic Pharmaceuticals’ JV receives USFDA approval for Clobetasol Propionate Ointment
    5th Mar 2019, 14:46 PM

    Clobetasol Propionate Ointment USP, 0.05%, has an estimated market size of US$ 63 million for twelve months ending December 2018 according to IQVIA

    Read More
  • Alembic Pharma gets USFDA’s nod for Acetazolamide Extended-Release Capsules
    20th Feb 2019, 11:24 AM

    Alembic has a cumulative total of 87 ANDA approvals from USFDA

    Read More
  • Alembic gets USFDA’s nod for Moxifloxacin Ophthalmic Solution
    15th Feb 2019, 10:55 AM

    The company has a cumulative total of 86 ANDA approvals (73 final approvals and 13 tentative approvals) from USFDA

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.